Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited
Key Takeaways
- Orforglipron is an investigational once-daily oral GLP-1 receptor agonist developed by Eli Lilly, not approved by the FDA as of May 2026
- It is a small molecule, not a peptide, which means no reconstitution, no injection, and no fasting requirement (unlike Rybelsus)
- The ACHIEVE-1 phase 3 readout (April 2025) reported approximately 14.7% mean weight loss at 36 mg over 72 weeks in type 2 diabetes patients
- Cross-trial efficacy sits roughly on par with injectable semaglutide and below tirzepatide, with the oral format as the key differentiator
- FormBlends does not sell, supply, or compound orforglipron; small-molecule oral drugs do not enter the 503A compounding pathway even during shortages
Direct answer
Orforglipron is Eli Lilly's investigational once-daily oral GLP-1 receptor agonist. It is a small molecule rather than a peptide, which lets it survive stomach acid and be taken as a pill rather than an injection. The ACHIEVE-1 phase 3 trial reported approximately 14.7% mean weight loss at the 36 mg dose over 72 weeks. It is not FDA-approved as of May 2026, and FormBlends does not sell, supply, or compound it.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What orforglipron is, in plain terms
- Why a pill matters: the peptide problem
- How orforglipron differs from Rybelsus
- The discovery story: Chugai to Lilly
- The clinical program: ACHIEVE and ATTAIN
- What ACHIEVE-1 actually showed
- Side effects and tolerability
- Where orforglipron sits in the GLP-1 landscape
- The contrary view: why oral might not win
- Decision framework for patients waiting
- FAQ
- Sources
What orforglipron is, in plain terms
Orforglipron is a drug that does what semaglutide and tirzepatide do, by a different route and in a different shape. It activates the GLP-1 receptor, which sits on cells in the pancreas, gut, and brain. When activated, that receptor triggers insulin release, slows stomach emptying, and reduces appetite signaling in the hypothalamus.
The shape difference is the part that matters commercially. Semaglutide, liraglutide, and tirzepatide are peptides, which are short chains of amino acids. They look like small proteins, and like proteins they get chewed apart by digestive enzymes if you swallow them. That is why they are normally injected.
Orforglipron is a small molecule. It is built from carbon, nitrogen, oxygen, and hydrogen atoms arranged into a stable structure that resists digestion. It enters the bloodstream after oral absorption and binds the GLP-1 receptor, producing the same downstream effects as the injectable peptides.
That structural choice make availables a different patient experience: a tablet, no needles, no refrigeration, no reconstitution, no titration ritual involving sharps disposal. For patients who have avoided GLP-1 therapy because of injection anxiety, orforglipron represents a clean alternative.
Why a pill matters: the peptide problem
The pharmaceutical industry has spent decades trying to make oral peptides work. The reason is straightforward: patients prefer pills. Adherence to oral medications averages around 70-80% in chronic conditions, compared to 50-60% for injectables (Brown and Bussell, Mayo Clinic Proceedings 2011). Lower-friction administration generally produces better long-term outcomes.
The obstacle is biology. The human digestive tract evolved to break down peptides, because most dietary protein arrives as peptides and amino acids. Stomach acid (pH around 1.5-3.5) denatures proteins. Pepsin in the stomach and trypsin and chymotrypsin in the small intestine cleave peptide bonds. By the time material reaches the bloodstream, the peptide is fragments.
Semaglutide can be taken orally as Rybelsus, but it requires a special trick. The Rybelsus tablet contains an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), which temporarily protects the semaglutide and helps it cross the stomach lining. Even with SNAC, oral semaglutide has a bioavailability of approximately 0.4-1%, meaning more than 99% of the dose never reaches systemic circulation (Buckley et al., Science Translational Medicine 2018). Patients must take Rybelsus on an empty stomach with no more than 4 ounces of water, then wait at least 30 minutes before eating or drinking anything else.
Orforglipron bypasses all of this. As a small molecule, it does not need SNAC. It does not need fasting. Phase 1 pharmacokinetic studies reported bioavailability of approximately 6%, an order of magnitude higher than oral semaglutide (Saxena et al., The Lancet 2023). That is still low compared to typical small-molecule drugs, but high enough to be practical.
How orforglipron differs from Rybelsus
Patients sometimes assume orforglipron and Rybelsus are similar because both are oral GLP-1 medications. The structural and practical differences are significant.
| Feature | Rybelsus (oral semaglutide) | Orforglipron |
|---|---|---|
| Drug class | Peptide | Small molecule |
| Approval status | FDA-approved 2019 (diabetes) | Investigational, not approved (May 2026) |
| Frequency | Once daily | Once daily |
| Fasting required | Yes, 30+ minutes before food | No |
| Water restriction | No more than 4 oz | None reported |
| Absorption enhancer | SNAC required | None needed |
| Oral bioavailability | ~0.4-1% | ~6% |
| Mean weight loss (trial data) | ~3-8% (PIONEER trials, diabetes) | ~14.7% at 36 mg (ACHIEVE-1) |
| Manufacturer | Novo Nordisk | Eli Lilly |
The most practical difference for patients: orforglipron does not require the morning fasting protocol that has made Rybelsus difficult for many patients to use consistently. The Rybelsus dosing window (wake up, take pill, wait 30 minutes before coffee or breakfast) creates daily friction that compounds over months. Orforglipron is closer to a typical tablet, taken when convenient.
The discovery story: Chugai to Lilly
Orforglipron began at Chugai Pharmaceutical in Japan. Chugai's medicinal chemistry program screened for small molecules that could bind the GLP-1 receptor without being peptides. They found a candidate, OWL833, and Lilly licensed it in February 2018 for development.
Lilly renamed the compound LY3502970, then orforglipron. The Lilly development program ran through phase 1 (pharmacokinetics and safety in healthy volunteers), phase 2 (dose-finding in type 2 diabetes and obesity), and into the current phase 3 program (ACHIEVE and ATTAIN).
The licensing structure matters for downstream economics. Chugai retains a milestone-and-royalty interest, but Lilly holds the development, manufacturing, and commercialization rights worldwide outside Japan. The commercial product, if approved, will be a branded Lilly medication.
The clinical program: ACHIEVE and ATTAIN
Lilly structured the phase 3 program around two indications:
- ACHIEVE program: orforglipron in type 2 diabetes (analogous to Ozempic's diabetes indication)
- ATTAIN program: orforglipron in obesity without diabetes (analogous to Wegovy's obesity indication)
This dual-indication strategy mirrors the semaglutide playbook. Novo Nordisk launched semaglutide first for diabetes (Ozempic, 2017) and then secured a separate approval for obesity (Wegovy, 2021). The combined market is larger than either indication alone, and the two programs share most of the safety database.
Within ACHIEVE:
- ACHIEVE-1: monotherapy in adults with type 2 diabetes inadequately controlled with diet and exercise. Readout April 2025.
- ACHIEVE-2, ACHIEVE-3, ACHIEVE-4: combinations with metformin, SGLT2 inhibitors, and insulin. Readouts staggered through 2025-2026.
Within ATTAIN:
- ATTAIN-1: monotherapy in adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities. Positive readout reported in 2025.
- ATTAIN-2: orforglipron in obesity with type 2 diabetes.
The combined enrollment exceeds 6,000 patients across the program, which is the kind of safety database the FDA requires for a chronic-use weight-management drug.
What ACHIEVE-1 actually showed
ACHIEVE-1 randomized adults with type 2 diabetes to placebo or one of three orforglipron doses (3 mg, 12 mg, or 36 mg daily) for 72 weeks. The primary endpoint was change in HbA1c, with body weight as a key secondary endpoint.
The headline results, reported by Lilly in April 2025:
- HbA1c reduction: approximately 1.3-1.6 percentage points at the highest dose, depending on baseline
- Mean weight loss at 36 mg: approximately 14.7%
- Mean weight loss at 12 mg: approximately 9-10%
- Mean weight loss at 3 mg: approximately 5-6%
- Placebo weight loss: approximately 1-2%
These numbers are dose-responsive in a clean way, which is good evidence the drug is doing what its mechanism predicts. The 14.7% figure at the top dose is comparable to STEP 1 semaglutide (Wilding et al. 2021, NEJM, reporting ~14.9% mean weight loss at 2.4 mg weekly).
For diabetes, the HbA1c reduction puts orforglipron in roughly the same efficacy band as semaglutide and tirzepatide. For obesity, the ATTAIN-1 readout (which is the pure obesity indication, without diabetes) is the more relevant data point and showed similar magnitude of weight loss.
Side effects and tolerability
Orforglipron shares the GLP-1 class side effect profile, which is GI-dominant.
From ACHIEVE-1 reporting:
- Nausea: approximately 16-30% depending on dose
- Vomiting: approximately 8-20%
- Diarrhea: approximately 12-22%
- Constipation: approximately 5-10%
- Decreased appetite: approximately 10-15%
These rates fall within the range seen in semaglutide and tirzepatide trials. The titration schedule (starting low and increasing every 4 weeks) is intended to manage the early-treatment GI burden. Discontinuation rates due to adverse events were approximately 5-10% across doses, comparable to STEP 1 (~7%) and SURMOUNT-1 (~7-9%).
One open question is hepatic safety. Phase 2 dose-finding studies reported small, generally reversible elevations in liver enzymes at higher doses. Lilly has stated these were not associated with clinical liver injury, but the FDA review will scrutinize liver findings carefully, given the chronic-use indication.
Where orforglipron sits in the GLP-1 landscape
The current state of the GLP-1 market and pipeline:
| Drug | Class | Route | Approval status | Approx weight loss |
|---|---|---|---|---|
| Semaglutide (Wegovy/Ozempic) | Peptide GLP-1 | Injection, weekly | FDA-approved | ~15% (STEP 1) |
| Tirzepatide (Zepbound/Mounjaro) | Peptide GLP-1/GIP | Injection, weekly | FDA-approved | ~22.5% (SURMOUNT-1, 15 mg) |
| Retatrutide | Peptide GLP-1/GIP/glucagon | Injection, weekly | Phase 3, not approved | ~24% (phase 2, 12 mg) |
| Liraglutide (Saxenda/Victoza) | Peptide GLP-1 | Injection, daily | FDA-approved | ~8% (SCALE) |
| Rybelsus (oral semaglutide) | Peptide GLP-1 | Oral daily, fasting | FDA-approved (diabetes) | ~3-8% (PIONEER) |
| Orforglipron | Small-molecule GLP-1 | Oral daily, no fasting | Phase 3, not approved | ~14.7% (ACHIEVE-1, 36 mg) |
| Danuglipron | Small-molecule GLP-1 (Pfizer) | Oral | Discontinued for obesity 2025 | ~8-13% (phase 2) |
Orforglipron's most likely positioning is the patient who would benefit from a GLP-1 but refuses or cannot tolerate weekly injections. That includes a meaningful slice of needle-averse patients, plus people who travel frequently and find injection storage and timing difficult.
The contrary view: why oral might not win
Most GLP-1 commentary assumes the oral pill will displace some share of injectable use. The counter-argument is worth taking seriously.
First, daily dosing is harder than weekly dosing. The standard objection to injectables is the needle, but once patients clear that barrier, weekly cadence is genuinely lower-friction than daily. Compliance data on chronic medications consistently shows higher adherence with less-frequent regimens (Coleman et al., Current Medical Research and Opinion 2012).
Second, orforglipron's weight loss efficacy at the highest dose appears to land roughly on par with semaglutide and below tirzepatide. For the patient prioritizing maximum weight loss, an injectable triple-agonist or even a GLP-1/GIP outperforms an oral GLP-1 monoagonist. Mechanism still wins on efficacy.
Third, pricing is a question mark. Lilly's commercial pattern with Zepbound has been to price at parity with Wegovy and above semaglutide alternatives. There is no guarantee orforglipron will be substantially cheaper than injectable Zepbound or Wegovy. The marginal cost-of-goods for a small molecule is far lower than for a peptide, but list price reflects strategy, not COGS.
Fourth, the compounding market does not extend to orforglipron. Patients who currently access compounded semaglutide or tirzepatide at $200-400/month from 503A pharmacies cannot get a compounded oral small molecule. If orforglipron launches at $1,000+/month list price, the price-sensitive segment of the market will stay on compounded injectables.
Decision framework for patients waiting
If you are weighing whether to wait for orforglipron or start something now, the right answer depends on your specific situation.
If you have not started any GLP-1 yet, and your BMI is in the obese range: waiting carries risk. Obesity is associated with cardiovascular, metabolic, and joint complications that accumulate over time. Starting an FDA-approved or compounded injectable now and possibly switching later is generally a better risk-adjusted strategy than waiting an uncertain 12-18+ months.
If your only objection to starting is the needle, and you are otherwise medically stable: the wait may be tolerable if it is short. But orforglipron's FDA approval timeline is not fully under Lilly's control. The PDUFA review process can extend, and post-approval supply can be constrained. A 6-month wait can easily become an 18-month wait.
If you are already on semaglutide or tirzepatide and tolerating it well: there is no clear reason to switch when orforglipron approves, unless cost or convenience tips the balance. Efficacy is your primary criterion, and the injectables remain at least as effective as the projected oral options.
If you have severe needle phobia that has prevented therapy entirely: waiting for orforglipron is a reasonable choice, with the caveat that the wait is uncertain. Discuss bridging strategies with your clinician, including supervised injection education, anxiolytic premedication, or alternative weight management while you wait.
FAQ
What is orforglipron?
Orforglipron is an investigational oral GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide, tirzepatide, and retatrutide (which are all injectable peptides), orforglipron is a small molecule taken as a once-daily pill. It is not FDA-approved as of May 2026 and is currently in phase 3 trials under the ACHIEVE and ATTAIN programs.
Is orforglipron a peptide?
No. Orforglipron is a non-peptide small molecule that binds the GLP-1 receptor. This distinction matters: peptide GLP-1s like semaglutide and liraglutide degrade in the stomach if swallowed, which is why most are injected. Orforglipron's small-molecule structure survives oral administration and does not require fasting before dosing.
How does orforglipron differ from Rybelsus?
Rybelsus is oral semaglutide, the peptide form of the same active drug found in Ozempic and Wegovy. It requires fasting administration and a special absorption enhancer (SNAC). Orforglipron is a different molecule entirely, a non-peptide small molecule that can be taken with or without food and has higher and more predictable oral bioavailability.
Who makes orforglipron?
Orforglipron is developed by Eli Lilly. It was originally discovered by Chugai Pharmaceutical (Japan) and licensed to Lilly in 2018. Lilly conducted phase 1, 2, and 3 development. The internal code name was LY3502970.
What is the ACHIEVE phase 3 program?
ACHIEVE is Lilly's phase 3 trial program for orforglipron in type 2 diabetes. ACHIEVE-1, the first readout (April 2025), showed mean weight loss of approximately 14.7% at the 36 mg daily dose over 72 weeks. The companion ATTAIN program studies orforglipron specifically for obesity, with ATTAIN-1 reporting positive efficacy and safety in 2025.
Will orforglipron work as well as Ozempic or Zepbound?
Cross-trial comparisons are imperfect, but the available data suggest orforglipron sits between semaglutide and tirzepatide on weight loss. ACHIEVE-1 reported ~14.7% mean weight loss, comparable to STEP 1 semaglutide (~14.9%) and below SURMOUNT-1 tirzepatide at 15 mg (~22.5%). Direct head-to-head trials have not been published.
Is orforglipron FDA-approved?
As of May 2026, orforglipron is not FDA-approved. Lilly has indicated it expects to file for approval based on the ACHIEVE and ATTAIN phase 3 results. A regulatory decision is anticipated but not guaranteed in 2026. This medication is investigational, and FormBlends does not sell, supply, or compound orforglipron.
When can I get orforglipron from FormBlends?
FormBlends does not offer orforglipron and has no path to offer it. Orforglipron is a small-molecule drug protected by patent and developed exclusively by Lilly. Unlike injectable peptides that 503A pharmacies can compound during shortages, small-molecule oral drugs do not enter the compounding pathway. If approved, orforglipron will be available only through Lilly as a branded medication.
Related guides
- Oral vs Injectable GLP-1: Why a Pill Took So Long to Make
- Retatrutide vs Orforglipron: Oral vs Injectable Comparison 2026
- How Does Orforglipron Work? The Pharmacology, Explained
- What Is Danuglipron? The Rise and Fall of Pfizer's Oral GLP-1
- Why Was Danuglipron Discontinued? Pfizer's Walk-Away from the Oral GLP-1 Race
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989-1002. (STEP 1)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387:205-216. (SURMOUNT-1)
- Saxena AR, Frias JP, Brown LS, et al. Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist orforglipron for the treatment of adults with obesity. The Lancet. 2023;401:1881-1891.
- Eli Lilly and Company. ACHIEVE-1 Phase 3 results, press release. April 17, 2025.
- Eli Lilly and Company. ATTAIN-1 Phase 3 results, press release. 2025.
- Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018;10:eaar7047.
- Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clinic Proceedings. 2011;86(4):304-314.
- Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. Current Medical Research and Opinion. 2012;28(5):669-680.
- U.S. Food and Drug Administration. Rybelsus (semaglutide tablets) Prescribing Information. 2019.
- U.S. Food and Drug Administration. Wegovy (semaglutide injection) Prescribing Information. 2021.
- U.S. Food and Drug Administration. Zepbound (tirzepatide injection) Prescribing Information. 2023.
- Chugai Pharmaceutical Co. License agreement with Eli Lilly for OWL833 (orforglipron). Press release. February 2018.
- Pfizer Inc. Discontinuation of danuglipron obesity program. Press release. April 2025.
Footer disclaimers
Platform Disclaimer. FormBlends offers physician-supervised weight management using FDA-approved and 503A-compounded medications. This page is educational. Orforglipron is investigational and not FDA-approved. FormBlends does not prescribe, dispense, or compound orforglipron, and we have no commercial relationship with Eli Lilly.
Compounded Medication Notice. Where we reference compounded semaglutide or tirzepatide, those are prepared by licensed 503A pharmacies under physician prescription. Compounded medications are not FDA-approved and are not therapeutically equivalent to the branded products. Small-molecule oral drugs like orforglipron cannot be compounded by 503A pharmacies and are available only as branded products if approved.
Results Disclaimer. Weight loss outcomes vary by individual. Phase 3 trial averages do not predict individual outcomes. Long-term weight maintenance depends on continued therapy plus sustained behavior change.
Trademark Notice. Orforglipron is a development name for an investigational compound owned by Eli Lilly and Company. Rybelsus, Ozempic, and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or Chugai Pharmaceutical.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →